Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes

N. Suksomboon,N. Poolsup,T. Prasit
DOI: https://doi.org/10.1111/j.1365-2710.2011.01295.x
2012-06-01
Journal of Clinical Pharmacy and Therapeutics
Abstract:What is known and Objective:  Telmisartan is an angiotensin receptor blocker (ARB) originally developed for the treatment of hypertension. It can also partially activate peroxisome proliferator‐activated receptor (PPAR)‐γ, which may improve insulin sensitivity. This effect may prove useful in hypertensive patients with insulin resistance or diabetes mellitus. Such activity is more marked than that observed with other ARBs. This systematic review and meta‐analysis evaluated the benefit of telmisartan on insulin sensitivity compared with that of other ARBs in hypertensive patients who had either insulin resistance or diabetic states.
What problem does this paper attempt to address?